Evidence map›Paper›PMID 35470354›Full record

ArticleThe American journal of case reports2022

A Case of Synthetic Cannabinoid (K2)-Induced Posterior Reversible Encephalopathy Syndrome (PRES).

Haider Ghazanfar, Aruna Muthumanickam, Zaheer Qureshi, Faryal Altaf, Cosmina Zeana, Sridhar Chilimuri

Open access · hybridAbstract readCase Reports
In one paragraph

Article in The American journal of case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Haider GhazanfarDepartment of Internal Medicine, BronxCare Health System, Bronx, NY, USA.
Aruna MuthumanickamDepartment of Internal Medicine, BronxCare Health System, Bronx, NY, USA.ORCID 0000-0002-7748-3448
Zaheer QureshiDepartment of Internal Medicine, BronxCare Health System, Bronx, NY, USA.
Faryal AltafDepartment of Internal Medicine, Continental Medical College, Lahore, Pakistan.
Cosmina ZeanaDivision of Infectious Diseases, Department of Internal Medicine, BronxCare Health System, Bronx, NY, USA.
Sridhar ChilimuriDepartment of Internal Medicine, BronxCare Health System, Bronx, NY, USA.
Montefiore Health System · USContinental (Canada) · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND K2 is an artificially synthesized cannabinoid (SCB), manufactured as a non-consumption herbal incense but increasingly misused as a recreational drug. Posterior reversible encephalopathy syndrome (PRES) is a rare clinical and radiological entity characterized by brain edema, often in the setting of acute hypertension. Cases of PRES caused by recreational drug use have been reported in the literature. CASE REPORT We report an unusual case of PRES after consumption of K2 in a 24-year-old healthy woman who presented with episodic agitation and altered mental status. Magnetic resonance imaging showed nonspecific subtle high T2/FLAIR (fluid-attenuated inversion recovery) signal intensities in the region of the posterior parietal and occipital cortices. Her extensive drug screen report was positive for K2. Her mental status improved over the course of 3 weeks and she had returned to her baseline at 3-month follow-up. CONCLUSIONS Our case highlights the importance of having a high clinical suspicion in patients presenting with altered mental status and a history of recreational drug use. K2 is not detected by routine urine drug testing, so a high level of clinical suspicion is required to request an extensive drug screen. It is important for the physician to counsel active synthetic cannabinoid users regarding these rare complications.

Indexed as

Brain EdemaCannabinoidsHypertensionPosterior Leukoencephalopathy SyndromeAdultFemaleHumansMagnetic Resonance ImagingYoung AdultCannabinoids

Identifiers

PMID35470354
PMCPMC9059105
OpenAlexW4221013450

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.